Chemotherapeutic Interventions Against Tuberculosis

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2013 Nov 28

PMID 24281707

Citations 4

Authors

Neeraj Shakya

Gaurav Garg

Babita Agrawal

Rakesh Kumar

Affiliations

Soon will be listed here.

Abstract

Tuberculosis is the second leading cause of infectious deaths globally. Many effective conventional antimycobacterial drugs have been available, however, emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has overshadowed the effectiveness of the current first and second line drugs. Further, currently available agents are complicated by serious side effects, drug interactions and long-term administration. This has prompted urgent research efforts in the discovery and development of new anti-tuberculosis agent(s). Several families of compounds are currently being explored for the treatment of tuberculosis. This review article presents an account of the existing chemotherapeutics and highlights the therapeutic potential of emerging molecules that are at different stages of development for the management of tuberculosis disease.

Citing Articles

Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors.

Alexandrova L, Khandazhinskaya A, Matyugina E, Makarov D, Kochetkov S Microorganisms. 2022; 10(7).

PMID: 35889017 PMC: 9322969. DOI: 10.3390/microorganisms10071299.

Novel isoniazid derivative as promising antituberculosis agent.

Volynets G, Tukalo M, Bdzhola V, Derkach N, Gumeniuk M, Tarnavskiy S Future Microbiol. 2020; 15:869-879.

PMID: 32662670 PMC: 8097507. DOI: 10.2217/fmb-2019-0085.

Investigation of 5'-Norcarbocyclic Nucleoside Analogues as Antiprotozoal and Antibacterial Agents.

Khandazhinskaya A, Matyugina E, Solyev P, Wilkinson M, Buckheit K, Buckheit Jr R Molecules. 2019; 24(19).

PMID: 31546633 PMC: 6804079. DOI: 10.3390/molecules24193433.

Novel 5'-Norcarbocyclic Pyrimidine Derivatives as Antibacterial Agents.

Khandazhinskaya A, Alexandrova L, Matyugina E, Solyev P, Efremenkova O, Buckheit K Molecules. 2018; 23(12).

PMID: 30477147 PMC: 6321083. DOI: 10.3390/molecules23123069.

References

Vanheusden V, Van Rompaey P, Munier-Lehmann H, Pochet S, Herdewijn P, Van Calenbergh S . Thymidine and thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. Bioorg Med Chem Lett. 2003; 13(18):3045-8. DOI: 10.1016/s0960-894x(03)00643-7. View

Stover C, Warrener P, VanDevanter D, Sherman D, Arain T, Langhorne M . A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000; 405(6789):962-6. DOI: 10.1038/35016103. View

Dinakaran M, Senthilkumar P, Yogeeswari P, China A, Nagaraja V, Sriram D . Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation. Bioorg Med Chem Lett. 2007; 18(3):1229-36. DOI: 10.1016/j.bmcl.2007.11.110. View

Rai D, Johar M, Srivastav N, Manning T, Agrawal B, Kunimoto D . Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides. J Med Chem. 2007; 50(19):4766-74. DOI: 10.1021/jm070391t. View

Jaso A, Zarranz B, Aldana I, Monge A . Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents. J Med Chem. 2005; 48(6):2019-25. DOI: 10.1021/jm049952w. View

Heifets L . MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother. 1988; 32(8):1131-6. PMC: 172364. DOI: 10.1128/AAC.32.8.1131. View

McIlleron H, Willemse M, Werely C, Hussey G, Schaaf H, Smith P . Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis. 2009; 48(11):1547-53. DOI: 10.1086/598192. View

Scorpio A, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y . Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1997; 41(3):540-3. PMC: 163747. DOI: 10.1128/AAC.41.3.540. View

Nuermberger E, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, OBrien R . Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004; 170(10):1131-4. DOI: 10.1164/rccm.200407-885OC. View

10.

Walczak K, Gondela A, Suwinski J . Synthesis and anti-tuberculosis activity of N-aryl-C-nitroazoles. Eur J Med Chem. 2004; 39(10):849-53. DOI: 10.1016/j.ejmech.2004.06.014. View

11.

. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet. 1981; 1(8213):171-4. View

12.

Khoje A, Kulendrn A, Charnock C, Wan B, Franzblau S, Gundersen L . Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring. Bioorg Med Chem. 2010; 18(20):7274-82. DOI: 10.1016/j.bmc.2010.08.016. View

13.

Tortoli E, Dionisio D, Fabbri C . Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains. J Chemother. 2004; 16(4):334-6. DOI: 10.1179/joc.2004.16.4.334. View

14.

Gerson S, Kaplan S, Bruss J, Le V, Arellano F, Hafkin B . Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002; 46(8):2723-6. PMC: 127358. DOI: 10.1128/AAC.46.8.2723-2726.2002. View

15.

Donald P, Seifart H . Cerebrospinal fluid pyrazinamide concentrations in children with tuberculous meningitis. Pediatr Infect Dis J. 1988; 7(7):469-71. DOI: 10.1097/00006454-198807000-00003. View

16.

Horita Y, Takii T, Kuroishi R, Chiba T, Ogawa K, Kremer L . Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives. Bioorg Med Chem Lett. 2011; 21(3):899-903. DOI: 10.1016/j.bmcl.2010.12.084. View

17.

Heifets L, Sanchez T, Vanderkolk J, Pham V . Development of rifapentine susceptibility tests for Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998; 43(1):25-8. PMC: 89015. DOI: 10.1128/AAC.43.1.25. View

18.

Huitric E, Verhasselt P, Andries K, Hoffner S . In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2007; 51(11):4202-4. PMC: 2151410. DOI: 10.1128/AAC.00181-07. View

19.

Srivastav N, Rai D, Tse C, Agrawal B, Kunimoto D, Kumar R . Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models. J Med Chem. 2010; 53(16):6180-7. DOI: 10.1021/jm100568q. View

20.

Rai D, Johar M, Manning T, Agrawal B, Kunimoto D, Kumar R . Design and studies of novel 5-substituted alkynylpyrimidine nucleosides as potent inhibitors of mycobacteria. J Med Chem. 2005; 48(22):7012-7. DOI: 10.1021/jm058167w. View